Abstract: A display device and a wearable device. The display device may include at least one display panel comprising multiple subsidiary display panels, wherein images output from the subsidiary panels are extended to one another to form a single screen image and at least one multi-channel lens including multiple subsidiary lenses to provide multiple channels for light incident onto the subsidiary lenses, respectively, wherein the subsidiary display panels are associated with the subsidiary lenses, respectively, and the subsidiary display panels are inclined at a first angle from a reference plane so that their front surfaces face the respective subsidiary lenses.

Abstract: A knife storage device includes a storage main body in which a knife having a blade and a handle is stored, wherein the storage main body has a blade accommodation part in which the blade is accommodated and a handle loading part in which the handle is loaded, and the handle is loaded in the handle loading part so that the knife is stably stored.

Abstract: Provided are a binder for an electrode, a negative electrode for a secondary battery including the binder, and a secondary battery, in which an active material layer is prevented from lifting from a negative electrode base material. A binder forming an electrode of a secondary battery includes a binder particle and a temperature-sensitive polymer grafted on a surface of the binder particle.

Abstract: The present disclosure relates to a thermoplastic polyurethane composition for injection molding and a method for manufacturing the same. Specifically, the thermoplastic polyurethane composition includes 0.5% by weight to 10.0% by weight of a sulfonate diol, 13% by weight to 60% by weight of an isocyanate, 30% by weight to 70% by weight of an ether-containing polyester polyol, and 5% by weight to 40% by weight of a chain extender.

Abstract: A display device includes a display portion including a first surface, from which light is emitted in a first direction, and a second surface opposite to the first surface, a first optical portion disposed on the first surface, and a second optical portion disposed on the first surface to be spaced apart from the first optical portion in a second direction crossing the first direction. Each of the first and second optical portions includes a multi-channel lens through which the light from the first surface passes, a first infrared light source, a first camera, and a first lens frame coupled to the multi-channel lens in the first direction to support at least a portion of the multi-channel lens. The first lens frame may include a first recess structure in which the first infrared light source is disposed and a second recess structure in which the first camera is disposed.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: Disclosed are a solid electrolyte and method of manufacturing the same. The solid electrolyte may include a core including a first electrolyte represented by Chemical Formula 1, and a shell including a second electrolyte represented by Chemical Formula 2, and disposed on a surface of the core. LiaPSbX1c??[Chemical Formula 1] Here, a satisfies an equation 4?a?7, b satisfies an equation 3?b?7, c satisfies an equation 0?c?2, and X1 includes Br or I. LidPSeX2f??[Chemical Formula 2] Here, d satisfies an equation 4?d?7, e satisfies an equation 3?e?7, f satisfies an equation 0?f?2, X2 includes Cl or Br, and an ionic radius of X1 is greater than an ionic radius of X2.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.

Abstract: A method for preparing a porcine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Sus scrofa myoglobin MYG; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the porcine myoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the porcine myoglobin prepared in accordance with the method.

Abstract: Disclosed are an apparatus and method for diagnosing a battery of a vehicle. The apparatus includes storage that stores a threshold value for each accumulated driving distance section corresponding to a state of the vehicle, and a controller that collects vehicle state information and battery state information from a plurality of vehicles, determines a maximum voltage difference change rate of a battery cell for an accumulated driving distance for each vehicle, and diagnoses an abnormality in a battery provided in each vehicle based on the maximum voltage difference change rate of the battery cell for the accumulated driving distance of each vehicle and a threshold value corresponding to the maximum voltage difference change rate.

Abstract: Disclosed are a battery diagnosis apparatus for a vehicle and a method thereof. The battery diagnosis apparatus for the vehicle includes a communication device that provides a communication interface with a plurality of vehicles, and a controller that collects vehicle state information and battery state information from the plurality of vehicles, manages a maximum voltage difference change rate of battery cells for each cumulative mileage with respect to the plurality of vehicles, and diagnoses abnormalities in batteries provided in the plurality of vehicles based on the maximum voltage difference change rate of the battery cells for each cumulative mileage.

Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.

Abstract: An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus. The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.

Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.

Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.

Abstract: The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile. More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile, the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.